Cargando…

Hepatocellular Carcinoma Occurrence and Recurrence in Hepatitis C-infected Patients Treated with Direct-acting Antivirals

Introduction Multiple studies have shown the efficacy of the new direct-acting antivirals (DAAs) with a cure rate of over 90% in hepatitis C virus (HCV)-infected patients. Some recently published studies have suggested an increased incidence of de novo and recurrent hepatocellular carcinoma (HCC) in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Syed, Taseen, Fazili, Javid, Ali, Ijlal Akbar, Zhao, Daniel, Hughes, Diane, Mahmood, Sultan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2018
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166920/ https://www.ncbi.nlm.nih.gov/pubmed/30280052 http://dx.doi.org/10.7759/cureus.2843

Ejemplares similares

Immunization Against Hepatitis A Virus and Hepatitis B Virus in Patients with Chronic Liver Disease: Are We Doing a Good Job?
por: Tajammal, Rutaba, et al.
Publicado: (2018)

Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon?
por: Butt, Amna Subhan, et al.
Publicado: (2018)

Mystery of Hepatitis E Virus: Recent Advances in Its Diagnosis and Management
por: Ahmed, Aftab, et al.
Publicado: (2015)

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
por: Kishta, Sara, et al.
Publicado: (2020)

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C
por: Kawagishi, Naoki, et al.
Publicado: (2023)

Chilaiditi's Sign Associated with Acute Colonic Pseudo-obstruction: A Radiological Diagnosis
por: Syed, Taseen, et al.
Publicado: (2018)

Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate
por: Kamal, Ahmed, et al.
Publicado: (2022)

Direct-Acting Antiviral Treatment in Albanian Patients With Chronic Hepatitis C and Advanced Liver Fibrosis
por: Cuko, Liri, et al.
Publicado: (2022)

Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed
por: Hassany, Sahar M, et al.
Publicado: (2020)

De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents
por: Kuftinec, Gabriela, et al.
Publicado: (2018)

Correlation Between Serum Alpha-Fetoprotein and Tumour Size in Patients With Hepatocellular Carcinoma Treated With Direct-Acting Antivirals
por: Rusie, Daniel, et al.
Publicado: (2022)

Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
por: Lee, Chang Hun, et al.
Publicado: (2021)

Patterns of Hepatocellular Carcinoma After Direct Antiviral Agents and Pegylated-Interferon Therapy
por: Fatima, Tehreem, et al.
Publicado: (2020)

Treatment Outcomes of Hepatitis C-Infected Patients in Specialty Clinic vs. Primary Care Physician Clinic: A Comparative Analysis
por: Syed, Taseen Ahmed, et al.
Publicado: (2019)

Impact of direct-acting antiviral therapy for hepatitis C–related hepatocellular carcinoma
por: Lin, Wei-Chen, et al.
Publicado: (2020)

Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma
por: Tajiri, Kazuto, et al.
Publicado: (2022)

Decreased risk of hepatocellular carcinoma recurrence with direct-acting antivirals compared with no treatment for hepatitis C: a meta-analysis
por: Lui, Felix H., et al.
Publicado: (2020)

Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
por: Ahn, Young-Hwan, et al.
Publicado: (2021)

Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment
por: Ahn, Young-Hwan, et al.
Publicado: (2022)

The Complex Interplay Relationship between HCV Infection, Direct-Acting Antiviral Therapy, and Hepatocellular Carcinoma Occurrence
por: Cavalletto, Luisa, et al.
Publicado: (2023)

Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response
por: Itami-Matsumoto, Saori, et al.
Publicado: (2019)

Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals
por: Schietroma, Ivan, et al.
Publicado: (2018)

The use of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma
por: Economides, Minas, et al.
Publicado: (2017)

Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma
por: Kamp, William M., et al.
Publicado: (2019)

Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C
por: Tse, Chung Sang, et al.
Publicado: (2020)

Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals
por: Fukumoto, Tsuyoshi, et al.
Publicado: (2022)

Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
por: Frazzoni, Leonardo, et al.
Publicado: (2021)

Hepatocellular carcinoma recurrence after directly acting antivirals for chronic hepatitis C: a 2-year follow-up study
por: Kamal, Ahmed, et al.
Publicado: (2021)

Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer
por: Kuromatsu, Ryoko, et al.
Publicado: (2022)

Long‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antivirals
por: Ogawa, Eiichi, et al.
Publicado: (2021)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

The frequency of occurrence of Hepatocellular Carcinoma after direct antiviral therapy in Hepatitis C virus patients
por: Aziz, Bilal, et al.
Publicado: (2019)

Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma
por: Teng, Wei, et al.
Publicado: (2019)

The Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Hepatitis C Virus in Saudi Arabia: A Nationwide Study Based on the Saudi Ministry of Health Surveillance Data From 2017 to 2021
por: AL-Ahmari, Tasneem S., et al.
Publicado: (2023)

Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma
por: Ismail, Mohamed Saleh, et al.
Publicado: (2020)

Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment
por: Imai, Kenji, et al.
Publicado: (2020)

Hepatocellular carcinoma after direct‐acting antiviral drug treatment in patients with hepatitis C virus
por: Kogiso, Tomomi, et al.
Publicado: (2018)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Accelerated hepatocellular carcinoma recurrence rate after postoperative direct-acting antivirals treatment – preliminary report
por: Warzyszyńska, Karola, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_aaveel0i80s3ua7r3p2ttkh931